Figure 2
From: Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
Forest plots for progression-free survival (PFS) and overall survival (OS) with respect to low and high rilotumumab exposure and positive and negative tumour MET expression. Low rilotumumab exposure was defined as Cminss<94 μg ml−1, and high rilotumumab exposure was defined as Cminss⩾94 μg ml−1. MET positivity was defined as ⩾25% membranous staining of tumour cells at any intensity, and MET negativity was defined as <25% membranous staining. CI, confidence interval; ECX, epirubicin, cisplatin, and capecitabine; HR, hazard ratio.
